CEA Flashcards

1
Q

CEA

A
  • Analysis where inputs are measured in monetary values and outcomes in natural health units that indicate an improvement in health, such as cures, lives saved, and decreased blood pressure
  • *Most prevalent pharmacoeconomic analysis found in pharmacy literature
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

CEA Advantages

A
  • Health units are common outcomes routinely measured in clinical trials and outcomes studies, therefore familiar and acceptable to practitioners
  • Outcomes do not need to be converted to monetary values (as in CBA)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

CEA Disadvantages

A
  • Alternatives being compared must be measured in same clinical outcome units
  • Only one outcome can be compared at a time
  • Difficult to consider intangible costs (pain, nausea) in CEA
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Total Cost =

A

Cost/patient * # of patients

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

CCA

A
  • Cost Consequence Analysis
  • Analysis summarized in final table
  • Cost-effectiveness isn’t determined by a single value, but by a summary for each component provided
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Calculate CER

A
  • Average CER would tell you how much it costs to achieve a unit of outcome with each treatment
  • NOT comparative cost
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

ICER

A
  • Incremental Cost-Effectiveness Ratio
  • Estimate how much it will cost to achieve one more unit of benefit beyond what standard/baseline provides
  • Interpretation: To increase the number of SFD, need additional $___ for each SFD above ___
  • Tells you how much cost is increased per unit of effectiveness gained when compared to the next best treatment
  • Calculate for less effective/less cost or most effective/more cost treatments
  • DON’T CALCULATE/REPORT NEGATIVE ICER
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

LYG

A

Life year gained

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

ICER Equation

A

[Cost(New) - Cost(STD)]/[Effective(New) - Effect(STD)]

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Cost-Effective Plane

A
  • Quad I/Quad III - Trade-off
  • Quad II - Dominant
  • Quad IV - Dominated
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Higher Cost/Lower Effectiveness

A

New dominated by STD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Lower Cost/Higher Effectiveness

A

New dominates STD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

CEA Five Steps

A
  1. Make table of costs and effects
  2. Eliminate first order (strictly dominated) treatments
  3. Calculate ICER for each successive treatment
  4. Eliminate second order dominated (extended dominance) treatments
  5. Calculate final ratios
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

First Order Dominated

A
  • Program or treatment is more expensive AND provides less benefits/effects than another program (strongly dominated)
  • Never efficient, always eliminate
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Which treatment should we use?

A
  • ICER is effective but can’t be used alone to make final decision
  • Utilize fixed budget or WTP approaches to make decision
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Budget as Decision

A
  • Choice depends on size of budget
  • Goal: maximize health given fixed budget
  • Put non-dominated treatments in order of effectiveness/benefit
  • Given budget, move to highest level of total costs in order of incremental costs, may need to split funds towards TWO programs
  • Yields implied WTP value
17
Q

Budget Assumptions

A
  1. Patient uses only one treatment

2. You can split the budget between treatments

18
Q

Budget Between Two Costs?

A

-Use a mix of the two treatments

Set of Equations
P1 + P2 = 1
(P1 * Cost1) + (P2 * Cost 2) = Budget

  • Solve for percentages of P1 and P2
  • Yields different treatments for different patients
19
Q

WTP as Decision

A
  • “Willing” to spend for a gain in benefit
  • Choose option that covers the most costly treatment with an incremental ratio less than or equal to WTP (ICEP =< WTP)
  • Same treatment for patient in same groups
  • Yields a budget
20
Q

Limitations/Issues

A
  • Limited/applicable to the single measure of benefit they used
  • Difficult/impossible to compare treatments with different measures
  • Don’t tell you whether treatment is worth implementing, still need WTP or budget
  • Don’t always end up with population average effects: there is a risk
  • Sometimes use CE ratios instead of ICER in studies, misleading and doesn’t inform on resource allocation so avoid its use